MarketPeel
Insider Trading Intelligence
Pricing
…
ID

Ira Duarte

HRTX
EVP, CHIEF FINANCIAL OFFICER · HERON THERAPEUTICS, INC. /DE/ · CIK 0001488864
FILING MIX · LIFETIME62%/38%
BUYS
28
SELLS
17
TOTAL VALUE
$79.9K
COMPANIES
1
ACTIVE SINCE
Nov 2023
HOLDINGS NOW
261,073
AVG SELL PX
$0.92
TRADE KIND
SHOWING 45 / 45
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Ira Duarte, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+49.43%+1.06%+48.37%+48.37%—
14d1+100.00%+34.16%+1.37%+32.79%+32.79%—
30d1+100.00%+97.43%+4.67%+92.76%+92.76%—
60d1+100.00%+139.97%+5.91%+134.05%+134.05%—
90d1+100.00%+196.68%+11.19%+185.50%+185.50%—
180d1+100.00%+206.50%+17.06%+189.44%+189.44%—
1y1+100.00%+29.80%+31.86%-2.06%-2.06%—
2y1+100.00%+19.98%+52.23%-32.24%-32.24%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
HRTX · 261,073 shares · as of Jun 16, 2026
093,555187,110280,665374,220202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 28 buys / 17 sellsCOVERAGE · 11 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,555$0.38$1.4K261,073Jun 16, 2026Jun 17, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
12,500——264,628Jun 16, 2026Jun 17, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
12,500——12,500Jun 16, 2026Jun 17, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
11,694——128,638Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
13,535——252,128Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
13,535——203,027Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
11,694——227,570Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,874——215,876Apr 19, 2026Apr 21, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,874——27,120Apr 19, 2026Apr 21, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
11,695——140,332Jan 31, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
11,695——195,356Jan 31, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
216,561——216,561Jan 30, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
216,562——216,562Jan 30, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,875——30,994Jan 19, 2026Jan 20, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,875——183,661Jan 19, 2026Jan 20, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
11,694——179,786Oct 31, 2025Nov 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
11,694——152,027Oct 31, 2025Nov 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,874——168,092Oct 19, 2025Oct 21, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,874——34,869Oct 19, 2025Oct 21, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
11,695——163,721Jul 31, 2025Aug 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
11,695——164,218Jul 31, 2025Aug 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,874——152,523Jul 19, 2025Jul 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,874——38,743Jul 19, 2025Jul 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
12,500——25,000Jun 16, 2025Jun 17, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
12,500——148,649Jun 16, 2025Jun 17, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
11,694——175,416Apr 30, 2025May 2, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
11,694——136,149Apr 30, 2025May 2, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,875——124,455Apr 19, 2025Apr 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,875——42,617Apr 19, 2025Apr 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
374,220——374,220Jan 31, 2025Feb 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
187,110——187,110Jan 31, 2025Feb 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,874——120,580Jan 19, 2025Jan 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,874——46,492Jan 19, 2025Jan 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,874——50,366Oct 19, 2024Oct 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,874——108,001Oct 19, 2024Oct 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,875——104,127Jul 19, 2024Jul 22, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,875——54,240Jul 19, 2024Jul 22, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
12,500——100,252Jun 16, 2024Jun 17, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
12,500——37,500Jun 16, 2024Jun 17, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
3,874——58,115Apr 19, 2024Apr 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
3,874——88,874Apr 19, 2024Apr 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Chief Financial Officer
1,122$2.64$3.0K87,752Apr 19, 2024Apr 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
371,935——371,935Jan 19, 2024Jan 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
61,989——61,989Jan 19, 2024Jan 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Chief Financial Officer
85,000$0.89$75.6K85,000Nov 16, 2023Nov 17, 2023 ↗View →
Other insiders · HRTX
Loading peer insiders…
About this filer
CIK 0001488864
ROLE
EVP, Chief Financial Officer
PRIMARY
HRTX
COMPANIES
1
ACTIVE SINCE
Nov 2023
MARKETPEEL · /INSIDER/0001488864DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback